User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial.

Primary tabs

Vandenberghe, Rik Van Laere, Koen Ivanoiu, Adrian [UCL] Salmon, Eric Bastin, Christine Brooks, David J

The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.

Document type Article de périodique (Journal article) – Article de recherche – Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
Access type Accès restreint
Publication date 2010
Language Anglais
Journal information "Annals of Neurology" - Vol. 68, no. 3, p. 319-29 (2010)
Peer reviewed yes
Publisher JohnWiley & Sons, Inc. ((United States) Hoboken)
issn 0364-5134
e-issn 1531-8249
Publication status Publié
Affiliations UCL - SSS/IONS/NEUR - Clinical Neuroscience
UCL - (SLuc) Service de neurologie
MESH Subject Aged ; Alzheimer Disease - radionuclide imaging ; Radiopharmaceuticals - diagnostic use ; Sensitivity and Specificity ; Benzothiazoles - diagnostic use ; Brain - metabolism, radionuclide imaging ; Cognition Disorders - radionuclide imaging ; Diagnostic Imaging ; Fluorodeoxyglucose F18 - analogs & derivatives, diagnostic use ; Humans ; Middle Aged ; Positron-Emission Tomography - methods
Links
  1. Klunk, J Neurosci, 23, 2086 (2003)
  2. Klunk William E., Engler Henry, Nordberg Agneta, Wang Yanming, Blomqvist Gunnar, Holt Daniel P., Bergström Mats, Savitcheva Irina, Huang Guo-Feng, Estrada Sergio, Ausén Birgitta, Debnath Manik L., Barletta Julien, Price Julie C., Sandell Johan, Lopresti Brian J., Wall Anders, Koivisto Pernilla, Antoni Gunnar, Mathis Chester A., Långström Bengt, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B : Imaging Amyloid in AD with PIB, 10.1002/ana.20009
  3. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G., PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis, 10.1093/brain/awm191
  4. Ikonomovic Milos D., Klunk William E., Abrahamson Eric E., Mathis Chester A., Price Julie C., Tsopelas Nicholas D., Lopresti Brian J., Ziolko Scott, Bi Wenzhu, Paljug William R., Debnath Manik L., Hope Caroline E., Isanski Barbara A., Hamilton Ronald L., DeKosky Steven T., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, 10.1093/brain/awn016
  5. Leinonen Ville, Assessment of β-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound B, 10.1001/archneur.65.10.noc80013
  6. Fodero-Tavoletti M. T., Smith D. P., McLean C. A., Adlard P. A., Barnham K. J., Foster L. E., Leone L., Perez K., Cortes M., Culvenor J. G., Li Q.-X., Laughton K. M., Rowe C. C., Masters C. L., Cappai R., Villemagne V. L., In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies, 10.1523/jneurosci.0630-07.2007
  7. Nelissen N., Vandenbulcke M., Fannes K., Verbruggen A., Peeters R., Dupont P., Van Laere K., Bormans G., Vandenberghe R., A  amyloid deposition in the language system and how the brain responds, 10.1093/brain/awm133
  8. Rowe C. C., Ng S., Ackermann U., Gong S. J., Pike K., Savage G., Cowie T. F., Dickinson K. L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W. E., Mathis C. A., Price J. C., Masters C. L., Villemagne V. L., Imaging  -amyloid burden in aging and dementia, 10.1212/01.wnl.0000261919.22630.ea
  9. Johnson Keith A., Gregas Matt, Becker John A., Kinnecom Catherine, Salat David H., Moran Erin K., Smith Erin E., Rosand Jonathan, Rentz Dorene M., Klunk William E., Mathis Chester A., Price Julie C., DeKosky Steven T., Fischman Alan J., Greenberg Steven M., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy, 10.1002/ana.21164
  10. Rabinovici Gil D., Jagust William J., Furst Ansgar J., Ogar Jennifer M., Racine Caroline A., Mormino Elizabeth C., O'Neil James P., Lal Rayhan A., Dronkers Nina F., Miller Bruce L., Gorno-Tempini Maria Luisa, Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia, 10.1002/ana.21451
  11. Edison P, Rowe C C, Rinne J O, Ng S, Ahmed I, Kemppainen N, Villemagne V L, O'Keefe G, Nagren K, Chaudhury K R, Masters C L, Brooks D J, Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography, 10.1136/jnnp.2007.127878
  12. Wolk David A., Price Julie C., Saxton Judy A., Snitz Beth E., James Jeffrey A., Lopez Oscar L., Aizenstein Howard J., Cohen Ann D., Weissfeld Lisa A., Mathis Chester A., Klunk William E., DeKosky Steven T., Amyloid imaging in mild cognitive impairment subtypes, 10.1002/ana.21598
  13. Pike K. E., Savage G., Villemagne V. L., Ng S., Moss S. A., Maruff P., Mathis C. A., Klunk W. E., Masters C. L., Rowe C. C.,  -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease, 10.1093/brain/awm238
  14. Reiman E. M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S. A., Langbaum J. B. S., Alexander G. E., Klunk W. E., Mathis C. A., Price J. C., Aizenstein H. J., DeKosky S. T., Caselli R. J., Fibrillar amyloid-  burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, 10.1073/pnas.0900345106
  15. Morris John C., Roe Catherine M., Xiong Chengjie, Fagan Anne M., Goate Alison M., Holtzman David M., Mintun Mark A., APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging, 10.1002/ana.21843
  16. Verhoeff, Am J Geriatr Psychiatry, 12, 584 (2004)
  17. Small Gary W., Kepe Vladimir, Ercoli Linda M., Siddarth Prabha, Bookheimer Susan Y., Miller Karen J., Lavretsky Helen, Burggren Alison C., Cole Greg M., Vinters Harry V., Thompson Paul M., Huang S.-C., Satyamurthy N., Phelps Michael E., Barrio Jorge R., PET of Brain Amyloid and Tau in Mild Cognitive Impairment, 10.1056/nejmoa054625
  18. Tolboom N., Yaqub M., van der Flier W. M., Boellaard R., Luurtsema G., Windhorst A. D., Barkhof F., Scheltens P., Lammertsma A. A., van Berckel B. N.M., Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET, 10.2967/jnumed.108.056499
  19. Rowe Christopher C, Ackerman Uwe, Browne William, Mulligan Rachel, Pike Kerryn L, O'Keefe Graeme, Tochon-Danguy Henry, Chan Gordon, Berlangieri Salvatore U, Jones Gareth, Dickinson-Rowe Kerryn L, Kung Hank P, Zhang Wei, Kung Mei Ping, Skovronsky Daniel, Dyrks Thomas, Holl Gerhard, Krause Sabine, Friebe Matthias, Lehman Lutz, Lindemann Stefanie, Dinkelborg Ludger M, Masters Colin L, Villemagne Victor L, Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, 10.1016/s1474-4422(08)70001-2
  20. Koole M., Lewis D. M., Buckley C., Nelissen N., Vandenbulcke M., Brooks D. J., Vandenberghe R., Van Laere K., Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging, 10.2967/jnumed.108.060756
  21. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., Bormans G., Brooks D. J., Vandenberghe R., Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease, 10.2967/jnumed.109.063305
  22. Petersen Ronald C., Smith Glenn E., Waring Stephen C., Ivnik Robert J., Tangalos Eric G., Kokmen Emre, Mild Cognitive Impairment : Clinical Characterization and Outcome, 10.1001/archneur.56.3.303
  23. Scheinin, J Nucl Med, 48, 128 (2007)
  24. McNamee R. L., Yee S.-H., Price J. C., Klunk W. E., Rosario B., Weissfeld L., Ziolko S., Berginc M., Lopresti B., DeKosky S., Mathis C. A., Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements, 10.2967/jnumed.108.057612
  25. Andersson Jesper L. R., Thurfjell Lennart, Implementation and Validation of a Fully Automatic System for Intra- and Interindividual Registration of PET Brain Scans : , 10.1097/00004728-199701000-00027
  26. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M., Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain, 10.1006/nimg.2001.0978
  27. Lopresti, J Nucl Med, 46, 1959 (2005)
  28. Chui, Evidence-based dementia practice, 106 (2003)
  29. Driscoll Ira, Resnick Susan M., Troncoso Juan C., An Yang, O'Brien Richard, Zonderman Alan B., Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly, 10.1002/ana.21031
  30. Fodero-Tavoletti M. T., Rowe C. C., McLean C. A., Leone L., Li Q.-X., Masters C. L., Cappai R., Villemagne V. L., Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias, 10.2967/jnumed.108.057984
  31. Holmes Clive, Boche Delphine, Wilkinson David, Yadegarfar Ghasem, Hopkins Vivienne, Bayer Anthony, Jones Roy W, Bullock Roger, Love Seth, Neal James W, Zotova Elina, Nicoll James AR, Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, 10.1016/s0140-6736(08)61075-2
  32. Rinne Juha O, Brooks David J, Rossor Martin N, Fox Nick C, Bullock Roger, Klunk William E, Mathis Chester A, Blennow Kaj, Barakos Jerome, Okello Aren A, de LIano Sofia Rodriguez Martinez, Liu Enchi, Koller Martin, Gregg Keith M, Schenk Dale, Black Ronald, Grundman Michael, 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, 10.1016/s1474-4422(10)70043-0
Bibliographic reference Vandenberghe, Rik ; Van Laere, Koen ; Ivanoiu, Adrian ; Salmon, Eric ; Bastin, Christine ; et. al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial.. In: Annals of Neurology, Vol. 68, no. 3, p. 319-29 (2010)
Permanent URL http://hdl.handle.net/2078.1/107559